On Feb. 9th 2022, Dr. Neil Berinstein of the Sunnybrook Cancer Research Institute provided us with an update on the BRAWM trial. That trial combines the standard-of-care Bendamustine + Rituximab, but adds in a BTK inhibitor, Acalabrutinib.
He also gave us an view of how Covid impacts WM patients.
And there was time for Q&A on both topics.
View the video here, on the WMFC YouTube channel.